Cheryl Peretz

Feb 11, 2024 | biorxiv.org | Vanessa Kennedy |Ritu Roy |Cheryl Peretz |Andrew Koh

AbstractMotivationRecently, single cell DNA sequencing (scDNAseq) and multimodal profiling with the addition of cell surface antibodies (scDAbseq) have provided key insights into cancer heterogeneity. Scaling these technologies across large patient cohorts, however, is cost and time prohibitive. Multiplexing, in which cells from unique patients are pooled into a single experiment, offers a possible solution.